Skip to Content

Join the 'Ulcerative Colitis - Maintenance' group to help and get support from people like you.

Ulcerative Colitis - Maintenance News

Inflammatory Bowel Disease May Raise Cancer Risk in Kids

Posted 1 day 22 hours ago by Drugs.com

THURSDAY, Sept. 21, 2017 – Children with inflammatory bowel disease (IBD) face an increased risk of cancer, a new study claims. The risk persists into adulthood, and is especially elevated for gastrointestinal cancers, the researchers added. The "extent and duration of chronic inflammation might be the main driving mechanisms underlying the increased risk of cancer," the researchers suggested. The international team, led by Dr. Ola Olen, a pediatric gastroenterologist at Karolinska Institute in Stockholm, compared about 9,400 patients in Sweden who were diagnosed with IBD before age 18 to a control group of nearly 93,000 people without IBD. The risk of cancer up to an average age of 30 was 3.3 cases per 1,000 person years among those with IBD. That compared with 1.5 cases per 1,000 person years in the control group. So, the overall risk of cancer among people with IBD is still low, the ... Read more

Related support groups: Cancer, Crohn's Disease, Colitis, Ulcerative Colitis, Crohn's Disease - Maintenance, Colorectal Cancer, Inflammatory Bowel Disease, Ulcerative Colitis - Active, Crohn's Disease - Acute, Ulcerative Colitis - Maintenance, Lymphocytic Colitis, Pseudomembranous Colitis, Noninfectious Colitis, Enterocolitis, Allergic Colitis

FDA Approves Cyltezo (adalimumab-adbm), a Biosimilar to Humira

Posted 30 Aug 2017 by Drugs.com

Ridgefield, Conn., August 29, 2017 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Cyltezo, a biosimilar to Humira, in a pre-filled syringe for the treatment of multiple chronic inflammatory diseases, including: moderate to severe active rheumatoid arthritis moderate to severe polyarticular juvenile idiopathic arthritis** active psoriatic arthritis active ankylosing spondylitis (an arthritis that affects the spine) moderate to severe active adult Crohn’s disease moderate to severe active ulcerative colitis moderate to severe plaque psoriasis “Cyltezo is the first biosimilar from Boehringer Ingelheim to be approved by the FDA and marks an important step towards our goal of providing new and more affordable treatment options to healthcare providers and patients,” said Ivan Blanarik, Senior Vice President and Head of The ... Read more

Related support groups: Rheumatoid Arthritis, Psoriasis, Humira, Crohn's Disease, Psoriatic Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Crohn's Disease - Maintenance, Plaque Psoriasis, Ulcerative Colitis - Active, Crohn's Disease - Acute, Juvenile Rheumatoid Arthritis, Ulcerative Colitis - Maintenance, Juvenile Idiopathic Arthritis, Adalimumab, Humira Pen, Amjevita, Cyltezo

Scientists Spot Genes Behind Crohn's, Ulcerative Colitis

Posted 29 Jun 2017 by Drugs.com

THURSDAY, June 29, 2017 – Researchers say they've come closer to pinpointing genes linked with inflammatory bowel diseases such as Crohn's and ulcerative colitis. For the study, the investigators examined the genomes of nearly 68,000 people. Of the regions of the genome associated with inflammatory bowel disease (IBD), 18 could be traced to a single genetic variant with more than 95 percent certainty. "We have taken the biggest ever data set for IBD and applied careful statistics to narrow down to the individual genetic variants involved," said study co-author Dr. Jeffrey Barrett, from the Wellcome Trust Sanger Institute in the United Kingdom. "Now we have a clearer picture of which genes do and do not play a role in the disease. We are zooming in on the genetic culprits of IBD," he said in an institute news release. The findings could lead to improved effectiveness of current ... Read more

Related support groups: Prednisone, Methylprednisolone, Crohn's Disease, Prednisolone, Ulcerative Colitis, Hydrocortisone, Medrol, Dexamethasone, Cortisone, Triamcinolone, Crohn's Disease - Maintenance, Betamethasone, Inflammatory Bowel Disease, Budesonide, Ulcerative Colitis - Active, Decadron, Crohn's Disease - Acute, Entocort, Ulcerative Colitis - Maintenance, Solu-Medrol

Arthritis Drug Shows Promise for Ulcerative Colitis

Posted 4 May 2017 by Drugs.com

WEDNESDAY, May 3, 2017 – A new study finds that people with moderate to severe ulcerative colitis who haven't done well on other treatments may find relief with Xeljanz (tofacitinib), a drug currently used to treat arthritis. Ulcerative colitis is a chronic inflammatory bowel disease. It affects about 700,000 Americans, according to the Crohn's and Colitis Foundation (CCF). The illness causes inflammation, irritation, swelling and sores on the lining of the large intestine. Symptoms include diarrhea with blood or pus and abdominal discomfort, according to CCF. "There is still a substantial unmet need for new treatments for patients with ulcerative colitis," said study lead author Dr. William Sandborn. He is professor of medicine and chief of the division of gastroenterology at the University of California, San Diego. Xeljanz targets certain proteins involved in the body's inflammatory ... Read more

Related support groups: Ulcerative Colitis, Ulcerative Colitis - Active, Ulcerative Colitis - Maintenance, Xeljanz, Tofacitinib, Xeljanz XR

FDA Approves Renflexis (infliximab-abda), a Biosimilar to Remicade

Posted 27 Apr 2017 by Drugs.com

INCHEON, Korea – April 24, 2017 – Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Renflexis (infliximab-abda), a biosimilar referencing Remicade®i (infliximab), across all eligible indications. In the US, Renflexis is indicated for reducing signs and symptoms in patients with adult and pediatric Crohn’s disease, adult ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, and for the treatment of adult plaque psoriasis. Renflexis is the first Samsung Bioepis product approved for marketing in the United States (US). “Since our company was established five years ago, we have strived day in and day out to realize the promise of biosimilars for patients across the United States by offering them treatment options at a lower cost. We hope this regulatory milestone will bring us a step closer to achievin ... Read more

Related support groups: Rheumatoid Arthritis, Crohn's Disease, Psoriatic Arthritis, Remicade, Ulcerative Colitis, Ankylosing Spondylitis, Crohn's Disease - Maintenance, Plaque Psoriasis, Ulcerative Colitis - Active, Crohn's Disease - Acute, Ulcerative Colitis - Maintenance, Infliximab, Renflexis

New Meds Make Inroads Against Crohn's Disease

Posted 13 Apr 2017 by Drugs.com

THURSDAY, April 13, 2017 – Fewer Americans with Crohn's disease are ending up in the hospital than in the past, according to a new federal study. Crohn's is a chronic inflammatory bowel disorder that often leads to surgery for most with the disease. Hospitalization rates for Crohn's disease remained stable in the United States between 2003 and 2013. That's a change from a study done from 1998 to 2004 that saw more than 4 percent increases in Crohn's hospitalizations each year, researchers with the U.S. Centers for Disease Control and Prevention said. The stable hospital rates are likely due to the 1998 introduction of a new class of biologic drugs. Examples of these medications used to treat Crohn's disease include: adalimumab (Humira), infliximab (Remicade), certolizumab (Cimzia) and ustekinumab (Stelara), according to the U.S. National Institute of Diabetes and Digestive and Kidney ... Read more

Related support groups: Humira, Crohn's Disease, Remicade, Ulcerative Colitis, Crohn's Disease - Maintenance, Inflammatory Bowel Disease, Ulcerative Colitis - Active, Stelara, Cimzia, Crohn's Disease - Acute, Ulcerative Colitis - Maintenance, Infliximab, Adalimumab, Ustekinumab, Inflectra, Amjevita, Certolizumab

Special Diet May Be Boon for Kids With Crohn's, Colitis

Posted 10 Jan 2017 by Drugs.com

MONDAY, Jan. 9, 2017 – Children with Crohn's disease and ulcerative colitis may be able to achieve relief without medications by eating a special diet, a small study suggests. The diet includes non-processed foods, such as fruits, vegetables, meats and nuts. Over 12 weeks, the diet appeared to ease all signs of these inflammatory bowel diseases in eight of the 10 affected children, researchers report. "The study shows that without other intervention, other changes, we can improve individuals' clinical as well as laboratory markers," said study author Dr. David Suskind. He's a professor of pediatrics and director of clinical gastroenterology at Seattle Children's Hospital. "I'm not surprised," Suskind added, "primarily because preliminary studies ... opened our eyes to the idea that diet had an impact." Inflammatory bowel disease (IBD) affects about 1.6 million Americans, according to ... Read more

Related support groups: Crohn's Disease, Colitis, Ulcerative Colitis, Dietary Supplementation, Asacol, Crohn's Disease - Maintenance, Creon, Sulfasalazine, Inflammatory Bowel Disease, Ulcerative Colitis - Active, Pentasa, Lialda, Crohn's Disease - Acute, Ulcerative Colitis - Maintenance, Lactaid, Apriso, Mesalamine, Zenpep, Canasa, Pancrease

Amjevita OK'd to Treat Inflammatory Diseases

Posted 27 Sep 2016 by Drugs.com

MONDAY, Sept. 26, 2016 – Amjevita (adalimumab-atto) – a biosimilar drug similar to the popular anti-inflammatory drug Humira – has been approved by the U.S. Food and Drug Administration. Amjevita has been approved for moderate-to-severe rheumatoid arthritis; psoriatic arthritis; ankylosing spondylitis (an arthritis that affects the spine); Crohn's disease; ulcerative colitis; plaque psoriasis and juvenile idiopathic arthritis, the FDA said in a news release. Biological drugs are generally derived from a living organism and can come from many sources, including humans, animals, microorganisms or yeast, the FDA said. A biosimilar drug is a biological product that's sanctioned after its maker proves it is "highly similar" to an already-approved biologic drug. The manufacturer of the biosimilar drug must prove that the product has "no clinically meaningful differences" in safety, purity ... Read more

Related support groups: Rheumatoid Arthritis, Humira, Crohn's Disease, Psoriatic Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Crohn's Disease - Maintenance, Plaque Psoriasis, Ulcerative Colitis - Active, Crohn's Disease - Acute, Ulcerative Colitis - Maintenance, Juvenile Idiopathic Arthritis, Adalimumab, Amjevita

FDA Approves Amjevita (adalimumab-atto), a Biosimilar to Humira

Posted 26 Sep 2016 by Drugs.com

September 23, 2016 – The U.S. Food and Drug Administration today approved Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for multiple inflammatory diseases. Amjevita is approved for the following indications in adult patients: moderately to severely active rheumatoid arthritis; active psoriatic arthritis; active ankylosing spondylitis (an arthritis that affects the spine); moderately to severely active Crohn’s disease; moderately to severely active ulcerative colitis; and moderate to severe plaque psoriasis. Amjevita is also indicated for moderately to severely active polyarticular juvenile idiopathic arthritis in patients four years of age and older. Health care professionals should review the prescribing information in the labeling for detailed information about the approved uses. “This is the fourth FDA-approved biosimilar. The biosimilar pathway is still a new fr ... Read more

Related support groups: Rheumatoid Arthritis, Humira, Psoriasis, Crohn's Disease, Psoriatic Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Crohn's Disease - Maintenance, Plaque Psoriasis, Ulcerative Colitis - Maintenance, Adalimumab, Amjevita

Vitamin A Compound Might Aid in Colon Cancer Fight

Posted 30 Aug 2016 by Drugs.com

TUESDAY, Aug. 30, 2016 – Retinoic acid, a compound derived in the body from vitamin A, might have a role in suppressing colon cancer, new animal research suggests. "Retinoic acid has been known for years to be involved in suppressing inflammation in the intestine," said study senior author Dr. Edgar Engleman, professor of pathology and medicine at Stanford University School of Medicine in Palo Alto, Calif. Meanwhile, the development of colon cancer has been linked to inflammation. For example, inflammatory bowel disease, such as ulcerative colitis, has been associated with colon cancer, he said in a university news release. "We wanted to connect the dots and learn whether and how retinoic acid levels directly affect cancer development," Engleman added. When the researchers looked at mice with colon cancer, they saw lower levels of retinoic acid in the intestines of the mice. The ... Read more

Related support groups: Cancer, Ulcerative Colitis, Colorectal Cancer, Ulcerative Colitis - Active, A-25, Ulcerative Colitis - Maintenance, Vitamin A, Diagnosis and Investigation, Retinol, Familial Adenomatous Polyposis, Aquasol A, Vitamin A Topical, A/Fish Oil

Stool Transplant Soothes Tough-to-Treat Colitis in Study

Posted 23 May 2016 by Drugs.com

MONDAY, May 23, 2016 – Stool transplants helped ease debilitating symptoms and heal the colons of tough-to-treat ulcerative colitis patients, new research shows. Australian scientists said the findings could pave the way for such transplants to be used on a more widespread basis. Transferring fecal matter from healthy donors into these patients alters the composition of their gut bacteria, circumventing one of the drivers of ulcerative colitis, experts said. "We were not completely surprised by the study findings, as . . . smaller studies along with unpublished experience suggested repeated fecal microbiota transplantation may be an effective treatment for ulcerative colitis," said study author Dr. Sudarshan Paramsothy, a gastroenterologist at University of New South Wales. "This study shows that [stool transplant] is a very promising therapeutic option for ulcerative colitis ... Read more

Related support groups: Ulcerative Colitis, Ulcerative Colitis - Active, Ulcerative Colitis - Maintenance, Diagnosis and Investigation, Fecal Incontinence

Inflectra Approved as 'Biosimilar' to Remicade

Posted 7 Apr 2016 by Drugs.com

WEDNESDAY, April 6, 2016 – The U.S. Food and Drug Administration has approved its second-ever "biosimilar" drug, Inflectra, for adults with Crohn's disease, rheumatoid arthritis or chronic plaque psoriasis, among other prescribed uses. In a media release, the agency said Inflectra was biosimilar to Janssen Biotech's Remicade (infliximab), first licensed in 1998. A biosimilar drug is sanctioned based on its maker's ability to show that it is "highly similar" to an already-approved biological drug that is generally derived from a living organism, such as a person, animal, microorganism or yeast, the FDA said. The maker of a biosimilar drug also must prove that the product has no "clinically meaningful difference" in safety and effectiveness from the original drug, and that the newer product has only "minor differences in clinically inactive components" from the original. Inflectra's most ... Read more

Related support groups: Rheumatoid Arthritis, Psoriasis, Crohn's Disease, Psoriatic Arthritis, Remicade, Ulcerative Colitis, Ankylosing Spondylitis, Crohn's Disease - Maintenance, Plaque Psoriasis, Ulcerative Colitis - Active, Crohn's Disease - Acute, Ulcerative Colitis - Maintenance, Infliximab, Inflectra

Ultrasound Might Speed Up Digestive Drug Delivery: Animal Study

Posted 21 Oct 2015 by Drugs.com

WEDNESDAY, Oct. 21, 2015 – Ultrasound waves could be used to rapidly deliver drugs to the digestive system, new animal research suggests. This new approach to drug delivery might potentially benefit people with inflammatory bowel disease (IBD), such as Crohn's disease and ulcerative colitis. However, this new method of drug delivery hasn't yet been tested in humans. "With additional research, our technology could prove invaluable in both clinical and research settings, enabling improved therapies and expansion of research techniques applied to the [gastrointestinal] tract," said co-senior study author Daniel Blankschtein, a professor of chemical engineering at Massachusetts Institute of Technology (MIT) in Cambridge. "[Our study] demonstrates for the first time the active administration of drugs, including biologics, through the GI tract," he said in an MIT news release. The ... Read more

Related support groups: Crohn's Disease, Colitis, Ulcerative Colitis, Crohn's Disease - Maintenance, Inflammatory Bowel Disease, Ulcerative Colitis - Active, Crohn's Disease - Acute, Ulcerative Colitis - Maintenance, Diagnosis and Investigation

Childhood Abuse Linked to Ulcerative Colitis Later in Life

Posted 11 Sep 2015 by Drugs.com

FRIDAY, Sept. 11, 2015 – Adults who were physically or sexually abused as children may be at increased risk for the inflammatory bowel disease ulcerative colitis, a new study finds. University of Toronto researchers analyzed data from nearly 22,000 Canadians aged 18 and older. They found that those with a history of childhood abuse were nearly twice as likely to have ulcerative colitis as those who hadn't suffered abuse. In ulcerative colitis, inflammation and sores develop in the innermost lining of the large intestine, according to the Crohn's & Colitis Foundation of America. Symptoms include diarrhea, bloody stools and abdominal pain. "We found that one-quarter of adults with ulcerative colitis reported they had been physically abused during their childhood, compared to one in 10 of those without inflammatory bowel disease," study lead author Esme Fuller-Thomson, a professor in the ... Read more

Related support groups: Ulcerative Colitis, Ulcerative Colitis - Active, Ulcerative Colitis - Maintenance

Crohn's Disease, Colitis Tied to Anxiety in Study

Posted 4 Aug 2015 by Drugs.com

TUESDAY, Aug. 4, 2015 – People with inflammatory bowel disease, such as Crohn's disease or ulcerative colitis, have an increased risk for an anxiety disorder, especially women, a new study suggests. Inflammatory bowel disease (IBD) is a group of disorders that cause chronic inflammation of the digestive tract. "Patients with IBD face substantial chronic physical problems associated with the disease," lead author Esme Fuller-Thomson, a professor from the University of Toronto, said in a university news release. "The additional burden of anxiety disorders makes life much more challenging so this 'double jeopardy' must be addressed." The study authors looked at 269 Canadian adults who had been diagnosed with an inflammatory bowel disease. The researchers found that these patients were two times more likely to have had generalized anxiety disorder at some point in their lives than adults ... Read more

Related support groups: Anxiety, Generalized Anxiety Disorder, Panic Disorder, Anxiety and Stress, Post Traumatic Stress Disorder, Social Anxiety Disorder, Crohn's Disease, Colitis, Ulcerative Colitis, Crohn's Disease - Maintenance, Ulcerative Colitis - Active, Performance Anxiety, Crohn's Disease - Acute, Ulcerative Colitis - Maintenance, Lymphocytic Colitis, Allergic Colitis

Page 1 2 3 Next

Ask a Question

Further Information

Related Condition Support Groups

Ulcerative Colitis

Related Drug Support Groups

Asacol, sulfasalazine, Lialda, mercaptopurine, Apriso, mesalamine, Azulfidine, Asacol HD, Delzicol, view more... Sulfazine, Purinethol, Dipentum, olsalazine, FIV-ASA, Salofalk, Mesasal Enteric Coated, Azulfidine EN-tabs, Canasa Pac